AcelRx Pharmaceuticals

AcelRx Pharmaceuticals Current Assets

Delisted

The Current Assets of AcelRx Pharmaceuticals (ACRX) as of Oct 28, 2026 is 11.56 M USD. In the previous year, Current Assets was 19.56 M USD — a change of -40.91% (lower).

Current Assets

11.56 MUSD

YoY

-40.91%

Last updated:

Current Assets of AcelRx Pharmaceuticals is 2023 11.56 M USD. Current Assets of AcelRx Pharmaceuticals was 2022 19.56 M USD. It decreases by -40.91% lower compared to the previous year.

The AcelRx Pharmaceuticals Current Assets history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Current Assets
Date
Current Assets
Jan 1, 2016
89.02 M USD
Jan 1, 2017
63.38 M USD
Jan 1, 2018
107.99 M USD
Jan 1, 2019
71.67 M USD
Jan 1, 2020
46.80 M USD
Jan 1, 2021
55.53 M USD
Jan 1, 2022
19.56 M USD
Jan 1, 2023
11.56 M USD
The AcelRx Pharmaceuticals Current Assets history
YEARCurrent AssetsYoY
11.56 MUSD-40.91%
19.56 MUSD-64.78%
55.53 MUSD+18.66%
46.80 MUSD-34.71%
71.67 MUSD-33.64%
107.99 MUSD+70.39%
63.38 MUSD-28.80%
89.02 MUSD-25.17%
118.96 MUSD+55.92%
76.30 MUSD-27.03%
104.56 MUSD+69.28%
61.77 MUSD+61.92%
38.15 MUSD+560.08%
5.78 MUSD-55.35%
12.94 MUSD-38.31%
20.98 MUSD—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

AcelRx Pharmaceuticals Stock analysis

What does AcelRx Pharmaceuticals do? AcelRx Pharmaceuticals Inc. is a California-based company specializing in the manufacturing of pain relief medications. The company was founded in 2005 and has since become an innovator in the development of pain medications. AcelRx's business model involves selling its patented products to hospitals and other healthcare facilities, and it is currently expanding into the global market. The company focuses on developing pain medications for emergency medicine and palliative care, with a particular emphasis on delivering medications through sprays or injections for fast-acting relief. AcelRx offers products such as Zalviso, a pain reliever based on Fentanyl nasal sprays used for post-operative pain, and Dsuvia, a sublingual tablet containing the active ingredient Sufentanil for severe pain. The FDA has approved Dsuvia as safe and effective. AcelRx has also entered partnerships with other pharmaceutical companies, such as Grünenthal and Chinese company R-Pharm, to bring its products to the international market. The company is committed to investing in research and development for innovative pain relief solutions, including a new research program targeting the development of medications for neuropathic pain. AcelRx Pharmaceuticals is a positive example of how modern pharmaceuticals can improve healthcare and quality of life. The company has demonstrated its potential through dedication and continuous research and development, and it is likely to make even greater contributions in the future. AcelRx Pharmaceuticals is one of the most popular companies on Eulerpool.

Frequently Asked Questions about AcelRx Pharmaceuticals stock

Current Assets of AcelRx Pharmaceuticals is 11.56 M USD in 2023.

Current Assets of AcelRx Pharmaceuticals changed from 19.56 M USD to 11.56 M USD, representing a -40.91% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Current Assets AcelRx Pharmaceuticals since 2006 – with annual values, charts, and detailed analysis.

Current assets are assets expected to be converted to cash within one year, including cash, receivables, and inventory.

Current Assets's USD is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Current Assets's AcelRx Pharmaceuticals historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Balance Sheet — AcelRx Pharmaceuticals

All Key Metrics — AcelRx Pharmaceuticals